KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 90 filers reported holding KALVISTA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $7,312,386 | +12.8% | 759,334 | +5.4% | 2.22% | +10.5% |
Q2 2023 | $6,484,572 | +14.0% | 720,508 | -0.4% | 2.01% | -14.6% |
Q1 2023 | $5,687,056 | +1493.0% | 723,544 | +4761.9% | 2.35% | +1376.7% |
Q2 2021 | $357,000 | -72.2% | 14,882 | -70.2% | 0.16% | -77.3% |
Q1 2021 | $1,285,000 | – | 50,000 | – | 0.70% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 719,937 | $6,697,459 | 5.56% |
TCG Crossover Management, LLC | 3,395,495 | $22,953,546 | 4.05% |
VR Adviser, LLC | 2,916,667 | $19,716,669 | 3.32% |
TANG CAPITAL MANAGEMENT LLC | 3,196,446 | $21,607,975 | 3.14% |
Prosight Management, LP | 621,667 | $4,202,469 | 2.29% |
Opaleye Management Inc. | 923,200 | $6,240,832 | 2.17% |
GREAT POINT PARTNERS LLC | 1,055,801 | $7,137,215 | 1.40% |
Frazier Life Sciences Management, L.P. | 3,238,859 | $21,894,687 | 1.36% |
DAFNA Capital Management LLC | 616,032 | $4,164,376 | 1.17% |
Vivo Capital, LLC | 856,008 | $5,787 | 0.67% |